These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 37498350)

  • 41. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
    Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
    Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
    Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
    [No Abstract]   [Full Text] [Related]  

  • 43. First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up.
    Ancona E; Ruol A; Castoro C; Chiarion-Sileni V; Merigliano S; Santi S; Bonavina L; Peracchia A
    Ann Surg; 1997 Dec; 226(6):714-23; discussion 723-4. PubMed ID: 9409570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma.
    Sun R; Tian L; Wei LJ
    JAMA Surg; 2022 May; 157(5):458-459. PubMed ID: 35080625
    [No Abstract]   [Full Text] [Related]  

  • 45. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
    Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
    Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
    Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
    Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 48. Cocktail without hangover: in search for the optimal chemotherapy in the combined management of non-operable esophageal carcinomas.
    So B; Marcu LG; Olver I; Gowda R; Bezak E
    Acta Oncol; 2017 Jul; 56(7):899-908. PubMed ID: 28375694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
    BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer.
    Tomasello G; Ghidini M; Barni S; Passalacqua R; Petrelli F
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):649-660. PubMed ID: 28349718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
    Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
    Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus.
    Lin JW; Hsu CP; Yeh HL; Chuang CY; Lin CH
    J Chin Med Assoc; 2018 Jan; 81(1):18-24. PubMed ID: 29066057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surgical intervention after neoadjuvant therapy in esophageal cancer: a narrative review.
    Ke J; Xie Y; Liang J; Wang M; Lin W
    J Thorac Dis; 2023 Apr; 15(4):2261-2276. PubMed ID: 37197518
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.
    Valencia Julve J; Alonso Orduña V; Escó Barón R; López-Mata M; Méndez Villamón A
    Clin Transl Oncol; 2006 Jan; 8(1):22-30. PubMed ID: 16632436
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The role of neoadjuvant therapy in multimodality treatment of locally advanced esophageal squamous cell carcinoma: perspective from the NEOCRTEC5010 trial].
    Guo XF; Fang WT
    Zhonghua Wai Ke Za Zhi; 2021 Aug; 59(8):646-650. PubMed ID: 34192855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY TRANSHITAL ESOPHAGECTOMY IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: IMPACT OF PATHOLOGICAL COMPLETE RESPONSE.
    Alves IPF; Tercioti Junior V; Coelho Neto JS; Ferrer JAP; Carvalheira JBC; Pereira EB; Lopes LR; Andreollo NA
    Arq Bras Cir Dig; 2022; 34(3):e1621. PubMed ID: 35019133
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Current status of neoadjuvant chemotherapy for advanced esophageal cancer].
    Tanabe S; Shirakawa Y; Maeda N; Katsube R; Ohara T; Sakurama K; Noma K; Fujiwara T
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1612-4. PubMed ID: 24393865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
    BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.